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Abstract The World Health Organization fracture risk
assessment tool (FRAX) and the Garvan fracture risk
calculator are both widely available tools for individualized
fracture risk prediction in daily practice. The FRAX model
is implemented in several guidelines and most widely used
at present. However, clinicians should take into account the
differences between the models, especially with regard to
the effect of the number of falls, number and clustering of
previous fractures, and the number of clinical risk factors
on the outcome of predicted fracture risk. Further develop-
ment will be needed for optimal integration of bone- and
fall-related risks, clustering of fractures, and dosing of risk
factors to validate the models in different populations and
to validate the ability to select patients who will achieve
fracture risk reduction with anti-osteoporosis therapy.
FRAX may be used as the primary model, and in patients
with recurrent fractures and falls the use of the Garvan
model may be of additional value.
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Introduction
Osteoporotic fractures are an important cause of morbidity
[1] and are linked with significant risk for subsequent
fracture and mortality, in both women and men. Epidemi-
ologic studies from North America have estimated the
remaining lifetime risk of common fragility fractures in
white women 50 years of age to be 17.5% for hip fracture,
15.6% for clinically diagnosed vertebral fracture, and
16.0% for distal forearm fracture. Corresponding risks
among men are 6%, 5%, and 3%, respectively [2].
Data from the General Practice Research Database in the
United Kingdom (UK, which includes 6% of the UK
population) have indicated that the risk is similar in the UK.
The lifetime risk of any fracture was found to be 53.2% at
50 years of age in women, and 20.7% at the same age in
men. Thus, one in two women and one in five men who are
50 years of age will have an osteoporotic fracture in their
remaining lifetime [3]. Among women, the 10-year risk of
any fracture increased from 9.8% at 50 years of age to
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DOI 10.1007/s11914-010-0022-321.7% at 80 years of age, whereas among men the 10-year
risk remained fairly stable with advancing age with a 10-
year risk of any fractures of 7.1% at 50 years to 8.0% at
80 years.[3] The health burden of osteoporotic fractures is
likely to rise, which is partly due to an increased life
expectancy and to changes in lifestyle (eg, less exercises/
mobility, less calcium intake). Therefore, understanding the
epidemiology of this disease is essential in trying to develop
strategies to target individuals at high risk for fracture.
Assessment of Fracture Risk
Bone Mineral Density Measurement
In 1994, the World Health Organization published diagnostic
criteria for osteoporosis defined in terms of bone mineral
density (BMD) measurement with dual-energy X-ray absorp-
tiometryasa T-score≤−2.5standarddeviation(SD) below the
young mean [4]. Recently, it was proposed that the reference
standard should be based on BMD measurement made at the
femoral neck because this site has been the most extensively
validated, and provides a gradient of fracture risk as high as
or higher than that of many other techniques [5].
In prospective and cross-sectional epidemiologic studies
it has been shown that there is an inverse relationship
between bone mass and fracture. The risk of osteoporotic
fracture increases continuously as BMD declines, resulting
in a 1.5- to threefold increase in risk of fracture for each SD
decrease in BMD [6]. Advanced age and low BMD are
strongly associated with higher fracture risk in postmeno-
pausal women [7], and data from multiple randomized
controlled trials provide evidence for fracture prevention in
individual patients with osteoporosis [8]. Up to now, many
guidelines recommend the assessment of BMD in patients
with clinical risk factors (CRFs) as a selection for whom to
treat. Using T-scores has many benefits, because T-scores
are simple and widely used, have a good correlation with
fracture risk, and can detect some high-risk patients.
However, the majority of fractures occur in the large group
of older women without osteoporosis, but with BMD in the
osteopenic range [9]. Furthermore, several other indepen-
dent risk factors for fractures, over and above that reflected
by BMD, have been identified [10, 11]. Thus, BMD will
not reliably predict all individuals who will sustain a
fracture from those who will not.
Assessment of High-Risk Patients
The Fracture Risk Assessment Tool
Given the increasing evidence now suggesting that T-scores
alone are not optimal predictors of fracture risk, the World
Health Organization Metabolic Bone Disease Group recently
developed other ways to assess fracture risk. In 2008 the
fracture risk assessment tool (FRAX) was released using
CRFs with and without BMD for fracture risk predication in
men and women [1, 12]. The development of the FRAX tool
has been supported by organizations including the Interna-
tional Osteoporosis Foundation, National Osteoporosis
Foundation (NOF), the American Society for Bone and
Mineral Research, and the International Society for Clinical
Densitometry. The FRAX tool (http://www.shef.ac.uk/
FRAX) computes the 10-year probability of hip fracture or
a major osteoporotic fracture. A major osteoporotic fracture
is defined as a clinical spine, hip, forearm, and humerus
fracture. An estimation of the 10-year fracture probability is
calculated in men or women using age, body mass index,
and CRFs (Table 1)[ 13–22]. The 10-year risk of fractures
can be calculated with or without femoral neck BMD in the
model.
Probability models need to be calibrated to the epidemi-
ology of fracture and death for any particular region or
country, because of considerable variations in fracture
probability and mortality in different regions of the world
[7, 23]. Therefore, FRAX models have been developed
from study cohorts from Europe, North America, Asia, and
Australia. Additionally, in a Poisson regression model,
mortality is taken into account as a competing risk [24]. In
the absence of a FRAX model for a particular country, a
surrogate country should be chosen, based on the likelihood
that it is representative of the index country.
In recently updated guidelines, FRAX is included as a
tool for case finding for identifying postmenopausal women
at high risk for fractures, for selecting subjects who would
need a BMD measurement, and for treatment decisions
(NOF) in the United States [25] and (National Osteoporosis
Guideline Group [NOGG]), in collaboration with many
Societies) in the UK [26, 27]. It is expected that FRAX will
also be helpful in designing fracture prevention studies and
in reimbursement issues, as patients at increased probability
of fracture can be identified beyond currently accepted
reimbursement thresholds for BMD [28].
In spite of its strengths, FRAX also has limitations. First,
the model has not been validated in randomized clinical
intervention trials focusing on the prevention of fractures in
patients who are included based on FRAX data that are
available. In post hoc analyses of intervention studies with
clodronate and bazedoxifene, the estimation of an individ-
ual’s 10-year probability of fracture by the FRAX algorithm
identified patients at high risk for fracture who will respond
to antiresorptive therapy, irrespective of BMD results [29,
30, 31￿, 32].However, once femoral neck BMD and age are
known, the eight additional risk factors in FRAX did not
significantly improve the prediction of vertebral fracture in
post hoc analyses of the alendronate studies. A combination
132 Curr Osteoporos Rep (2010) 8:131–137of baseline radiographic vertebral fracture, femoral neck
BMD, and age was found to be the strongest predictor of
future vertebral fracture [33]. Further studies will be needed
to validate the efficacy of treatment in terms of fracture risk
reduction when subjects at high risk for fractures are being
treated based on FRAX in the absence of a morphometric
vertebral fracture, hip fracture, or a low BMD, which is the
case in most patients presenting with a nonvertebral fracture.
Second, FRAX can only be used in untreated patients. Third,
the increased subsequent fracture risk after an initial fracture
is considered constant over time in FRAX, so the calculation
by FRAX over a 10-year period does not take into account
the clustering in time of subsequent fracture risk after an
initial fracture. However, subsequent fracture risk fluctuates
over time and is highest within the first years after an initial
fracture, as has been shown for repeat vertebral, non-
vertebral, and hip fractures [34–36, 37￿]. Fourth, fall-related
risks were explicitly excluded from the FRAX calculations.
Reasons were the lack of standardized evaluation methods
and the lack of fracture prevention data with fall prevention
measures, which decrease the risk of falls (FRAX). However,
fall risks were recognized as a risk for fractures indepen-
dently of bone-related risks, especially for nonvertebral
fractures, including hip fractures [8, 38, 39]. Kayan et al.
[32] reported that fall risk does not significantly impact on
the antifracture efficacy of clodronate, suggesting that after
confirmation with other agents, fall risk may be incorporated
into risk assessment tools designed to target skeletal
therapies. Given this observation, it would be an additional
value to take fall risk into account in the assessment of
fracture risk. Finally, FRAX does not include several
additional risk factors for fractures, such as the number of
causes of secondary osteoporosis, the dose and duration of
glucocorticoid use [40], characteristics of previous fractures
(location, number, and severity) [41], and vitamin D
deficiency [42].
The Garvan Fracture Risk Calculator
In 2007, another prognostic nomogram for individualizing
the risk of hip fracture was developed based on the Dubbo
Osteoporosis Epidemiology Study data [43]. In a subse-
quent study, the model was extended for prediction of the
5- and 10-year risk of any fragility fracture [44￿]. The
model uses CRFs such as history of prior fracture (1, 2, or
more than 2), history of fall during the past 12 months (1, 2,
or more than 2), age, and BMD (Table 1). The authors
developed two models, one with weight and one with
BMD. The difference in predictive accuracy between the
model with BMD and the model with weight is only
modest, and therefore, if BMD is not available, the model
with weight can be used in clinical practice [44]. The
Garvan tool takes into account the history and number of
recent falls (1, 2, and >2) and the number of previous
fractures (1, 2, and >2). It also predicts more types of
fractures than FRAX. The Garvan tool allows 5- and 10-
year fracture calculations, whereas the FRAX calculates the
10-year fracture risk [44]. A limitation of the Garvan tool is
Table 1 Comparison of risk factors and predicted fracture risk
between the FRAX and Garvan fracture risk calculator
FRAX tool Garvan nomogram
Risk factors Risk factors
Age Age
Sex Sex
Body weight Body weight
a
Femoral neck BMD Femoral neck BMD
a
History of prior fractures
b History of prior fractures
after age 50 y
c
Height History of falls in the
previous 12 mo Parent with hip fracture
Current smoking
Glucocorticoid exposure
>3 mo ≥5 mg/d
Rheumatoid arthritis
Secondary osteoporosis
d
Alcohol ≥3 units/d
Predicted fractures
(10-y probability)
Predicted fractures (5- and
10-y probability)
Hip Hip
Spine Clinical spine
Wrist Wrist
Humerus Humerus
Pelvis
Rib
Sternum
Distal femur
Proximal tibia/fibula
Distal tibia/fibula
Patella
Hands and feet (not digits)
BMD bone mineral density, FRAX fracture risk assessment tool
aEither body weight or BMD is used in the Garvan nomogram.
bA previous fracture in adult life occurring spontaneously, or a fracture
arising from trauma that, in a healthy individual, would not have resulted
in a fracture.
cExcluding major fractures.
dThese include untreated hypogonadism in men and women (eg, premature
menopause, bilateral oophorectomy or orchidectomy), anorexia nervosa,
chemotherapy for breast cancer, hypopituitarism, inflammatory bowel disease
(eg, Crohn’s disease and ulcerative colitis), prolonged immobility (eg,
spinal cord injury, Parkinson’s disease, stroke, muscular dystrophy), ankylos-
ing spondylitis, organ transplantation, type 1 diabetes, thyroid disorders
(eg, untreated hyperthyroidism, overtreated hypothyroidism), chronic
obstructive pulmonary disease, osteogenesis imperfecta in adults,
chronic malnutrition, or malabsorption and chronic liver disease
Curr Osteoporos Rep (2010) 8:131–137 133that it does not include other risk factors as in FRAX, and
therefore, might underestimate fracture risk when many
CRFs are present. Another limitation is its availability only
in subjects older than 60 years of age and that it is based on
an Australian population only, in contrast to FRAX.
When comparing the FRAX and Garvan tool on a
theoretic basis, the outcome of the fracture probability of
both tools differs depending upon the risk profile of
patients. In patients without CRFs, the fracture risk
calculation is higher with the Garvan tool than with FRAX,
since the number of fractures predicted by Garvan is higher
than by FRAX [45]. Also, when using the Garvan tool,
calculated fracture risk increases according to the number
of previous fractures after 50 years of age and the number
of falls in the last 12 months, in contrast to FRAX (Fig. 1).
Conversely, calculated fracture risk increases with the
number of CRFs with FRAX, whereas Garvan does not
take additional CRFs into account (Fig. 2)[ 45]. In a recent
Australian cohort analysis, both approaches were reason-
ably accurate in women, but FRAX discriminated fracture
risk poorly in men [46]. However, it there is no available
Australian database for FRAX, and UK and US databases
were used instead in this study. In another recent study, in
which a comparison is made between both models in a
population of 2,012 Polish women, the mean conformity
for any fracture risk was 79.1% and for hip fracture 79.5%;
however, it appeared that for prediction of hip fractures, the
cumulative role of falls and multiple previous fractures was
stronger than other CRFs [38].
The Use of FRAX in Guidelines
Until recently, the majority of clinical guidelines for the
management of osteoporosis have made recommendations
for intervention based on BMD T-scores [1]. In 2008 the
NOGG in collaboration with many Societies in the UK
recommended an approach for decision making based on
fracture probabilities derived from FRAX that can be
applied to men and women. The NOGG provided inter-
vention thresholds (the fracture probability at which
intervention is recommended) and assessment thresholds
(the fracture probabilities at which a BMD test might or
might not be recommended). Probabilities of a major
osteoporotic and hip fracture can be plotted at the NOGG
website (http://www.shef.ac.uk/NOGG) available through
FRAX, showing whether the patients should be reassured,
need a BMD measurement, or can be considered for
treatment. The intervention threshold at each age is set at
a risk equivalent to that associated with a prior fracture and
therefore rises with age [27]. Men and women with 10-year
major fracture probabilities below the lower assessment
threshold can be reassured. Men and women with proba-
bilities above the upper assessment threshold can be
considered for treatment. Men and women with probabil-
ities between the upper and lower assessment threshold
should be referred for BMD measurements and their
fracture probability reassessed.
The NOF recommends using FRAX when the decision
to treat or not to treat is uncertain. It is primarily intended
for postmenopausal women and men 50 years of age and
older who have T-scores between −1.0 SD and −2.5 SD and
who are not on treatment, and who have not had spine or
hip fractures. The guideline recommends drug treatment if
the FRAX 10-year probability exceeds 20% for four major
fractures or 3% risk for hip fracture based on economic
models suggesting cost-effectiveness of osteoporosis treat-
ment above these percentages [25, 47, 48].
The use of FRAX as intended in both guidelines changes
current clinical management and may be difficult to
Fig. 1 Ten-year calculated risk
of osteoporotic fractures
according to the fracture risk
assessment tool (FRAX) (UK)
and Garvan tool based on the
number of recent falls (the last
12 months) and previous frac-
tures after 50 years of age
(women, 60 years, 70 kg,
170 cm, no bone mineral density
measurement)
134 Curr Osteoporos Rep (2010) 8:131–137interpret for clinicians. For example, there are patients with
one CRF who should be referred for a BMD measurement
according to the NOGG guide, and when having osteopo-
rosis (T-score ≤−2.5) should not be treated according to the
reassessed FRAX probability because it is too low to justify
treatment according to the NOGG. In contrast, according to
NOF guidelines, patients with osteopenia who have a 10-
year major fracture risk greater than 20% based on the
presence of CRFs would be treated despite the fact that they
do not have osteoporosis.
Additional interpretation issues may arise because a
discrepancy may exist between BMD values at the lumbar
spine and femoral neck, especially among women around
50 years of age who may have low lumbar spine BMD with
normal femoral neck BMD. It is anticipated that FRAX will
be incorporated into bone density software in the United
States in the near future, so that BMD results will be
combined with the FRAX 10-year fracture probability.
Patients and physicians will be routinely provided with
information on fracture risk that adds to that derived from
BMD alone [49]. Physicians should be aware of the fact
that BMD is a risk factor for fracture, and the association
between BMD and risk is a continuous one despite the T-
score cutoff of −2.5 SD that is used for the clinical
diagnosis of osteoporosis [50]. Conversely, they also need
to be educated about the strengths and limitations of FRAX
and how calculated risks can be used in clinical practice for
individual patients. Whether to add FRAX to a BMD result
in the report to the physician is thus still a matter of debate
[39, 49].
The FRAX tool may be inappropriate in a number of
situations, most notably when osteoporosis treatment is
clearly needed (eg, in the presence of a vertebral fracture),
but may be very useful for convincing patients who have
low 10-year fracture risks that osteoporosis treatment is
unnecessary even when the BMD values are in the lower
range and to show patients that fracture risk increases with
the occurrence of additional risk factors (eg, smoking,
recent insufficiency fracture, or glucocorticoid therapy)
regardless of BMD. In patients with high fall risk, a recent
previous fracture, and/or multiple previous fractures, the
10-year fracture risks may be underestimated by FRAX, as
shown with the use of the Garvan algorithm in such cases.
Conclusions
In daily practice, there is an urgent need for clinicians to
have a model that estimates the absolute fracture risk in
their patients, since decisions about whether or not to treat
patients with anti-osteoporotic drugs should be based on the
efficacy of these drugs, but also on the fracture risk. The
FRAX and the Garvan fracture risk calculator are both
widely available tools for individualized fracture risk
prediction in daily practice. The FRAX model is imple-
mented in the NOF, National Osteoporosis Society, and
NOGG guidelines and most widely used at present. Its
advantage is that it is easy to use in clinical practice for
selecting patients at high risk for fractures, thus it is useful
for clinical decision making, case finding and is a valuable
tool for patient education. Clinicians should take into
account the differences between the models especially with
respect to the effect of the number of falls and fractures on
fracture risk that is implemented in the Garvan model but
not in FRAX and the effect of the number of CRFs on
fracture risk in the FRAX, not in the Garvan model; they
also need to be aware of possible limitations of the models
when using them for individual patient management. Both
Fig. 2 Ten-year calculated risk
of osteoporotic fractures
according to the fracture risk
assessment tool (FRAX) (UK)
and Garvan tool based on the
number of clinical risk factors
(women, 60 years, 60 kg,
170 cm, T-score femoral
neck=−2.5)
Curr Osteoporos Rep (2010) 8:131–137 135models still need to be validated in different populations
before they can be generalized to other populations and
further studies will be needed to validate their contribution
in selecting patients who will achieve fracture risk
reduction with anti-osteoporosis therapy. Further studies
will be needed to develop a case-finding algorithm that
integrates bone- and fall-related risks, the clustering of
fractures, and the dosing of risk factors (eg, number and
severity of previous fractures, dose of glucocorticoids,
timing, and number of falls). With the current available
algorithms, a possible clinical application may be to use
FRAX as the primary model and to consider using Garvan
in patients with recurrent fractures and falls.
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